Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine

Scavone, Joseph M.; Greenblatt, David J.; Matlis, Rita; Harmatz, Jerold S.

doi:10.1007/bf00981141

Cited by 19 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 1 study with oxaprozin, only the oral clearance was found to be decreased (-20%), following a 10-day ranitidine treatment (Scavone et al 1986). The clinical consequences are unknown, but undoubtedly very limited due to the wide therapeutic margin of oxaprozin.…”

Section: Other Analgesicsmentioning

confidence: 95%

Side Effects of Ranitidine

et al. 1991

View full text Add to dashboard Cite

Ranitidine was first marketed in 1981; since then many patients have been treated such that much experience has been accumulated on the safety of this histamine H2-receptor antagonist in the treatment of gastroduodenal disease. A wide array of ranitidine-associated side effects has been described, but infrequently. As so much information is now available, the aim of this review is to assess the weight of evidence for a causal link between ranitidine and the reported side effects. Overall, ranitidine is well tolerated. The incidence of general side effects at less than 2% is very similar to placebo. Headaches, tiredness, dizziness and mild gastrointestinal disturbance (e.g. diarrhoea, constipation and nausea) are among the most frequent complaints, but have very seldom resulted in stopping treatment. Cardiovascular side effects are extremely rare and unpredictable with the usual doses of oral ranitidine (at most 1 in 1 million patients). They mostly comprise sinusal bradycardia and atrioventricular blockade, especially after rapid intravenous administration, receding after cessation of the drug. Clinical studies, however, have not shown a significant pharmacological effect of ranitidine on the cardiovascular system via H2-receptors, even though individual sensitivities cannot be ruled out in a few isolated reports. Ranitidine is unlikely to be directly hepatotoxic: a transient change in liver function tests has been noted in only 1 in 100 to 1 in 1000 patients. Several cases of mixed hepatitis have been reported, but very few were fully documented. The incidence of ranitidine-associated acute hepatitis has been estimated to be less than 1 in 100,000 patients. Neuropsychiatric complications may be less common and clinically quite similar to those reported with cimetidine, i.e. confusion, disorientation, hallucinations, delirium. These side effects have occurred especially in critically ill and multiple-therapy patients, or patients with chronic renal or hepatic failure, so that the direct causal link with ranitidine treatment was often difficult to ascertain. Even though an H2-receptor-mediated effect is an attractive hypothesis (since similar complications were noted with other H2-receptor antagonists), other mechanisms have been suggested to play a role, e.g. cholinergic or histaminic effects. The overall incidence of neuropsychiatric complications is probably markedly less than 1%. White cell injury (i.e. agranulocytosis) appears to be the most frequent haematological complication, even though case reports are very few and poorly documented.(ABSTRACT TRUNCATED AT 400 WORDS)

show abstract

Section: Other Analgesicsmentioning

confidence: 95%

Side Effects of Ranitidine

et al. 1991

View full text Add to dashboard Cite

show abstract

“…Aspirin je pokazao interakciju sa oksaprozinom vezanim za albumin [50]. Nisu utvrđene klinički značajne intrakcije oksaprozina prilikom istovremene primene sa antagonistima H 2 receptora, antacidima ili paracetamolom [51,52].…”

Section: Farmakokinetika Oksaprozinaunclassified

Oxaprozin: Synthesis, SAR study, physico-chemical characteristics and pharmacology

Božić¹,

Trišović²,

Valentić³

et al. 2011

Hem Ind

View full text Add to dashboard Cite

Oxaprozin (3-(4,5-difeniloksazol-2-yl)propanoic acid) is a nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of numerous inflammatory musculoskeletal diseases, including rheumatoid arthritis, osteoarthritis, tendonitis, ankylosing spondylitis and bursitis. It is the first representative member of the diaryl-substituted heterocyclic compounds, which have found clinical use as selective cyclooxygenase-2 (COX-2) inhibitors. U.S. Food and Drug Administration (FDA) approved its official use in 1992. Both anti-inflammatory and analgesic properties of oxaprozin are mainly due to the potent inhibition of COX. However, oxaprozin-induced benefits might be also regulated by other COX-independent pathways. It has been shown that oxaprozin induced direct proapoptotic effects in CD40L-treated human monocytes independently of COX inhibition. It also has several advantages in the treatment of inflammatory diseases in comparison to other NSAIDs such as aspirin, naproxen, indomethacin and phenylbutazone, which enabled oxaprozin to become one of the most used NSAIDs in America. Oxaprozin, as other members of the group of NSAIDs, can cause gastrointestinal complications, but significantly lower due to relatively high pKa value. In this paper, importance of oxaprozin in the treatment of arthritis and its pharmacokinetic properties were described, therewith its activity and side effects were compared with other commercially available anti-inflammatory drugs

show abstract

A review of interaction studies between non-steroidal anti-inflammatory drugs and H2-receptor antagonists or prostaglandin analogues

Dixon¹,

Page²

1992

Side-Effects of Anti-Inflammatory Drugs 3

View full text Add to dashboard Cite

Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine

Cited by 19 publications

References 14 publications

Side Effects of Ranitidine

Side Effects of Ranitidine

Oxaprozin: Synthesis, SAR study, physico-chemical characteristics and pharmacology

A review of interaction studies between non-steroidal anti-inflammatory drugs and H2-receptor antagonists or prostaglandin analogues

Contact Info

Product

Resources

About